Abstract
This paper aimed at reviewing the involvement of neuropeptides in various psychiatric diseases, particularly in depression, and anxiety disorders. General features of neuropeptides are first described, including the history of their discovery, their definition, classification, biosynthesis, transport, release, inactivation, as well as their interaction with specific neuronal receptors. The differences with classical neurotransmitters are mentioned, as well as the different patterns of co-transmission. Finally, different mechanisms, both at the cellular and at the systemic level, are proposed that may explain the involvement of these molecules in various psychiatric diseases. Indeed, at the cellular level, a neuropeptide can be involved in a psychiatric disease, either because it is co-localized with a classical neurotransmitter involved in a disease, or because the neuropeptide-containing neuron projects on a target neuron involved in the disease. At the systemic level, a neuropeptide can play a direct role in the expression of a symptom of the disease. This is illustrated by different exemples.
Keywords: anxiety, depression, psychiatric diseases, Neuropeptide
CNS & Neurological Disorders - Drug Targets
Title: Neuropeptides in Psychiatric Diseases: An Overview with a Particular Focus on Depression and Anxiety Disorders
Volume: 5 Issue: 2
Author(s): A. Surget, S. Leman, G. Griebel, C. Belzung and I. Yalcin
Affiliation:
Keywords: anxiety, depression, psychiatric diseases, Neuropeptide
Abstract: This paper aimed at reviewing the involvement of neuropeptides in various psychiatric diseases, particularly in depression, and anxiety disorders. General features of neuropeptides are first described, including the history of their discovery, their definition, classification, biosynthesis, transport, release, inactivation, as well as their interaction with specific neuronal receptors. The differences with classical neurotransmitters are mentioned, as well as the different patterns of co-transmission. Finally, different mechanisms, both at the cellular and at the systemic level, are proposed that may explain the involvement of these molecules in various psychiatric diseases. Indeed, at the cellular level, a neuropeptide can be involved in a psychiatric disease, either because it is co-localized with a classical neurotransmitter involved in a disease, or because the neuropeptide-containing neuron projects on a target neuron involved in the disease. At the systemic level, a neuropeptide can play a direct role in the expression of a symptom of the disease. This is illustrated by different exemples.
Export Options
About this article
Cite this article as:
Surget A., Leman S., Griebel G., Belzung C. and Yalcin I., Neuropeptides in Psychiatric Diseases: An Overview with a Particular Focus on Depression and Anxiety Disorders, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359682
DOI https://dx.doi.org/10.2174/187152706776359682 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD
Current Medicinal Chemistry Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Unmasking Sex-Based Disparity in Neuronal Metabolism
Current Pharmaceutical Design Olfactory Ensheathing Cells Protect Cortical Neuron Cultures Exposed to Hypoxia
CNS & Neurological Disorders - Drug Targets Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Perspectives on Emerging Biomarkers for Non-Invasive Assessment of Embryo Viability in Assisted Reproduction
Current Molecular Medicine The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets New Targets for Therapy in Polyglutamine (polyQ) Expansion Diseases
Current Drug Therapy Protective Substances Against Zinc-Induced Neuronal Death after Ischemia:Carnosine as a Target for Drug of Vascular Type of Dementia
Recent Patents on CNS Drug Discovery (Discontinued) Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?
Current Medicinal Chemistry Narcolepsy in Adolescents: A Review and Three Case Reports
Adolescent Psychiatry Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (thematic Issue: Functional Performance of L-Carnosine (β-Alanyl-L-Histidine) and Related Imidazole-Containing Dipeptides. Design and Modern Applications of Drug Delivery Systems (Nanosuspensions of Nanosize Materials, Mucoadhesive Drug Delivery Systems, Formulations of Transdermal Patches for Controlled Drug Delivery)
Recent Patents on Drug Delivery & Formulation Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Current Pharmaceutical Design